These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile ...
NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race ...
Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results